<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01024205</url>
  </required_header>
  <id_info>
    <org_study_id>OCTG-SuMR</org_study_id>
    <secondary_id>CDR0000660317</secondary_id>
    <secondary_id>EUDRACT-2006-004511-21</secondary_id>
    <secondary_id>REDA-4911</secondary_id>
    <secondary_id>MREC-07/Q0603/58</secondary_id>
    <secondary_id>PFIZER-OCTG-SuMR</secondary_id>
    <nct_id>NCT01024205</nct_id>
  </id_info>
  <brief_title>Sunitinib Malate Before and After Surgery in Treating Patients With Previously Untreated Metastatic Kidney Cancer</brief_title>
  <official_title>Upfront Sunitinib (SU011248) Therapy Followed by Surgery in Patients With Metastatic Renal Cancer: A Pilot Phase II Study [SuMR]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barts and the London School of Medicine and Dentistry</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the&#xD;
      enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib&#xD;
      malate before surgery may make the tumor smaller and reduce the amount of normal tissue that&#xD;
      needs to be removed. Giving sunitinib malate after surgery may kill any tumor cells that&#xD;
      remain after surgery.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving sunitinib malate before and after&#xD;
      surgery works in treating patients with metastatic kidney cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine if neoadjuvant sunitinib malate can achieve a clinical benefit of 70% or more&#xD;
           to the primary renal tumor prior to surgery and adjuvant sunitinib malate in patients&#xD;
           with metastatic renal cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the time to radiological progression in these patients.&#xD;
&#xD;
        -  Determine the overall survival of these patients.&#xD;
&#xD;
        -  Determine the proportion of patients suitable for nephrectomy after neoadjuvant&#xD;
           sunitinib malate.&#xD;
&#xD;
        -  Determine the translational endpoints.&#xD;
&#xD;
      OUTLINE: Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats&#xD;
      every 6 weeks for 3 courses. Approximately 2 weeks later, patients undergo a standard radical&#xD;
      nephrectomy with lymph node dissection. Beginning at least 2 weeks after surgery, patients&#xD;
      receive oral sunitinib malate on days 1-28. Courses repeat every 6 weeks in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      Blood and tissue samples may be collected periodically for laboratory studies.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 2 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neoadjuvant sunitinib malate achieving a clinical benefit of ≥ 70%</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to radiological progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients suitable for nephrectomy after neoadjuvant sunitinib malate</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Kidney Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sunitinib malate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed renal cell carcinoma&#xD;
&#xD;
               -  Measurable metastatic disease on CT/MRI imaging&#xD;
&#xD;
               -  Patients with suspicion of renal cancer on radiology must have a biopsy to&#xD;
                  confirm diagnosis of clear cell disease&#xD;
&#xD;
          -  No prior therapy for renal cancer&#xD;
&#xD;
          -  Judged by the treating physician to have the potential to derive clinical benefit from&#xD;
             this treatment&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1 x 10^9/L (without growth factor support)&#xD;
&#xD;
          -  Platelet count ≥ 75 x 10^9/L&#xD;
&#xD;
          -  Total bilirubin ≤ 2 times upper limit of normal (ULN) (except for patients with&#xD;
             Gilbert disease)&#xD;
&#xD;
          -  Serum creatinine ≤ 2 times ULN&#xD;
&#xD;
          -  Serum transaminases &lt; 5 times ULN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for ≥ 28 days after&#xD;
             completion of study therapy&#xD;
&#xD;
          -  Willing and able to comply with scheduled visits, treatment plan, and laboratory tests&#xD;
             and other study procedures&#xD;
&#xD;
          -  No congestive heart failure, myocardial infarction, or coronary artery bypass graft&#xD;
             within the past 6 months, or ongoing severe or unstable arrhythmia requiring&#xD;
             medication&#xD;
&#xD;
          -  No other severe acute or chronic medical or psychiatric condition, or abnormal&#xD;
             laboratory results that would impart, in the judgement of the investigator, excess&#xD;
             risk associated with study participation or study drug administration or would make&#xD;
             the patient inappropriate for entry into this study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 7 days since prior and no concurrent potent CYP3A inhibitors, including any&#xD;
             of the following:&#xD;
&#xD;
               -  Ketoconazole&#xD;
&#xD;
               -  Itraconazole&#xD;
&#xD;
               -  Clarithromycin&#xD;
&#xD;
               -  Erythromycin&#xD;
&#xD;
               -  Diltiazem&#xD;
&#xD;
               -  Verapamil&#xD;
&#xD;
               -  Delavirdine&#xD;
&#xD;
               -  Indinavir&#xD;
&#xD;
               -  Saquinavir&#xD;
&#xD;
               -  Ritonavir&#xD;
&#xD;
               -  Atazanavir&#xD;
&#xD;
               -  Nelfinavir&#xD;
&#xD;
          -  At least 12 days since prior and no concurrent potent CYP3A inducers, including any of&#xD;
             the following:&#xD;
&#xD;
               -  Rifampin&#xD;
&#xD;
               -  Rifabutin&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
               -  Phenobarbital&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  St. John's wort&#xD;
&#xD;
               -  Efavirenz&#xD;
&#xD;
               -  Tipranavir&#xD;
&#xD;
          -  Concurrent radiotherapy allowed provided sunitinib malate is stopped one day before&#xD;
             and resumed one day after radiotherapy&#xD;
&#xD;
          -  Concurrent coumarin-derivative anticoagulants (e.g., warfarin) allowed (≤ 2 mg/day)&#xD;
             for prophylaxis of thrombosis&#xD;
&#xD;
          -  No concurrent treatment with a drug having proarrhythmic potential (i.e., terfenadine,&#xD;
             quinidine, procainamide, disopyramide, sotalol, probucol, bepridil, haloperidol,&#xD;
             risperidone, indapamide, or flecainide)&#xD;
&#xD;
          -  No other concurrent investigational drug or participation in another clinical trial&#xD;
             (unless approved by the sponsor)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Powles, MD, MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barts and the London School of Medicine and Dentistry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orchid Clinical Trials Group at Barts and the London School of Medicine and Dentistry</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>EC1M 6BQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Powles T, Chowdhury S, Bower M, Saunders N, Lim L, Shamash J, Sarwar N, Sadev A, Peters J, Green J, Boleti K, Augwal S. The effect of sunitinib on immune subsets in metastatic clear cell renal cancer. Urol Int. 2011;86(1):53-9. doi: 10.1159/000319498. Epub 2010 Oct 26.</citation>
    <PMID>20975250</PMID>
  </results_reference>
  <verification_date>July 2011</verification_date>
  <study_first_submitted>December 1, 2009</study_first_submitted>
  <study_first_submitted_qc>December 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2009</study_first_posted>
  <last_update_submitted>August 9, 2013</last_update_submitted>
  <last_update_submitted_qc>August 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2013</last_update_posted>
  <keyword>clear cell renal cell carcinoma</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

